| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H25ClN2O |
| Molecular Weight | 344.878 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(C=C1)[C@@H]2[C@H]3CC[C@H](C3)[C@]24CCC(=N4)N5CCOCC5
InChI
InChIKey=KIYTZWUWLDEAMW-LNKGRISISA-N
InChI=1S/C20H25ClN2O/c21-17-5-2-14(3-6-17)19-15-1-4-16(13-15)20(19)8-7-18(22-20)23-9-11-24-12-10-23/h2-3,5-6,15-16,19H,1,4,7-13H2/t15-,16+,19+,20+/m0/s1
| Molecular Formula | C20H25ClN2O |
| Molecular Weight | 344.878 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Spiclamine (Epsilamine) is a hemostatic agent. It was administered to a total of 23 patients with urological diseases, including 8 postoperative cases. Marked effective, effective and ineffecgive responses were observed in 8, 10 and 5 cases respectively, making 78.3 % of effectiveness. In cases of so-called essential renal bleeding and prostatic disease, a particularly beneticial result was obtained making 93.3 % of marked effectiveness. No serious side effects was seen in all cases treated.
